CEA在结直肠癌中的研究进展
Research Progress of CEA in Colorectal Cancer
DOI: 10.12677/ACM.2023.132215, PDF,   
作者: 任广明, 刘嵩邈, 原居正：西安医学院，陕西 西安；郑建勇*：西京医院，陕西 西安
关键词: 癌胚抗原；CEA；CRC；肿瘤标记物；Carcinoembryonic Antigen； CEA； Colorectal Cancer； Tumor Markers
摘要: 结直肠癌(CRC)目前是全球第三大癌症，也是全球第二大癌症相关死亡原因。肿瘤标记物在CRC患者的检测和治疗中发挥着重要作用，而CEA是CRC临床诊疗中最常用的肿瘤标记物之一。在这篇综述中，我们描述了CEA在CRC筛查、诊断中的进展，以及CEA肿瘤疫苗、CEA靶向给药系统和荧光抗CEA抗体在CRC治疗中的研究进展。这些新的研究为CRC的诊疗提供了新的思路。
Abstract: Colorectal cancer (CRC) is currently the third leading cancer and the second leading cause of can-cer-related death worldwide. Tumor markers play an important role in the detection and treatment of colorectal cancer patients, and CEA is one of the most commonly used tumor markers in the clin-ical management of colorectal cancer. In this review, we describe advances in CEA in CRC screening and diagnosis, as well as research advances in CEA-based vaccines, CEA-targeted drug delivery sys-tems, and anti-CEA fluorescent antibodies in CRC treatment. These new studies provide new ideas for the diagnosis and treatment of CRC.
文章引用：任广明, 刘嵩邈, 原居正, 郑建勇. CEA在结直肠癌中的研究进展[J]. 临床医学进展, 2023, 13(2): 1561-1566. https://doi.org/10.12677/ACM.2023.132215

参考文献

[1] Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] 孙可欣, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11.
[3] Zhang, Y., Chen, Z. and Li, J. (2017) The Current Status of Treatment for Colorectal Cancer in China: A Systematic Review. Medicine, 96, e8242. [Google Scholar] [CrossRef] 
[4] Van Cutsem, E., Cervantes, A., Nordlinger, B. and Arnold, D. (2014) Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 25, iii1-iii9. [Google Scholar] [CrossRef] [PubMed]
[5] Duffy, M.J., et al. (2014) Tumor Markers in Colorectal Cancer, Gas-tric Cancer and Gastrointestinal Stromal Cancers: European Group on Tumor Markers 2014 Guidelines Update. Interna-tional Journal of Cancer, 134, 2513-2522. [Google Scholar] [CrossRef] [PubMed]
[6] Silsirivanit, A. (2019) Chapter Five-Glycosylation Markers in Cancer. In: Makowski, G.S., Ed., Advances in Clinical Chemistry, 89, Academic Press, Cambridge, 189-213. [Google Scholar] [CrossRef] [PubMed]
[7] Gold, P. and Freedman, S.O. (1965) Demonstration of Tu-mor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques. Journal of Experimental Medicine, 121, 439-462. [Google Scholar] [CrossRef] [PubMed]
[8] Gold, P. and Freedman, S.O. (1965) Specific Carcinoembryonic Anti-gens of the Human Digestive System. Journal of Experimental Medicine, 122, 467-481. [Google Scholar] [CrossRef] [PubMed]
[9] Beauchemin, N. and Arabzadeh, A. (2013) Carcinoembryonic Anti-gen-Related Cell Adhesion Molecules (CEACAMs) in Cancer Progression and Metastasis. Cancer and Metastasis Re-views, 32, 643-671. [Google Scholar] [CrossRef] [PubMed]
[10] Rodrigues, J.G., et al. (2018) Glycosylation in Cancer: Selected Roles in Tumour Progression, Immune Modulation and Metastasis. Cellular Immunology, 333, 46-57. [Google Scholar] [CrossRef] [PubMed]
[11] Rückert, F., Pilarsky, C. and Grützmann, R. (2010) Serum Tu-mor Markers in Pancreatic Cancer-Recent Discoveries. Cancers, 2, 1107-1124. [Google Scholar] [CrossRef] [PubMed]
[12] Sousa, A.R., Oliveira, M.J. and Sarmento, B. (2019) Impact of CEA-targeting Nanoparticles for Drug Delivery in Colorectal Cancer. Journal of Pharmacology and Experimental Ther-apeutics, 370, 657-670. [Google Scholar] [CrossRef] [PubMed]
[13] Hammarström, S. (1999) The Carcinoembryonic Antigen (CEA) Family: Structures, Suggested Functions and Expression in Normal and Malignant Tissues. Seminars in Cancer Biology, 9, 67-81. [Google Scholar] [CrossRef] [PubMed]
[14] Tiernan, J.P., et al. (2013) Carcinoembryonic Antigen Is the Preferred Biomarker for in Vivo Colorectal Cancer Targeting. British Journal of Cancer, 108, 662-667. [Google Scholar] [CrossRef] [PubMed]
[15] Lee, J.S., et al. (2013) Elevated Levels of Preoperative CA 15-3 and CEA Serum Levels Have Independently Poor Prognostic Significance in Breast Cancer. Annals of Oncology, 24, 1225-1231. [Google Scholar] [CrossRef] [PubMed]
[16] Feng, F., et al. (2017) Diagnostic and Prognostic Value of CEA, CA19-9, AFP and CA125 for Early Gastric Cancer. BMC Cancer, 17, Article No. 737. [Google Scholar] [CrossRef] [PubMed]
[17] Grunnet, M. and Sorensen, J.B. (2012) Carcinoembryonic Anti-gen (CEA) as Tumor Marker in Lung Cancer. Lung Cancer, 76, 138-143. [Google Scholar] [CrossRef] [PubMed]
[18] Lee, K J., et al. (2013) Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma. Yonsei Medical Journal, 54, 643-649. [Google Scholar] [CrossRef] [PubMed]
[19] Stockley, R.A., et al. (1986) Effect of Cigarette Smoking, Pulmo-nary Inflammation, and Lung Disease on Concentrations of Carcinoembryonic Antigen in Serum and Secretions. Thorax, 41, 17-24. [Google Scholar] [CrossRef] [PubMed]
[20] Kashiwabara, K., Nakamura, H. and Yokoi, T. (2001) Chrono-logical Change of serum Carcinoembryonic Antigen (CEA) Concentrations and Pulmonary Function Data after Cessation of Smoking in Subjects with Smoking-Associated CEA Abnormality. Clinica Chimica Acta, 303, 25-32. [Google Scholar] [CrossRef] 
[21] Fahy, B.N. (2014) Follow-up after Curative Resection of Colorectal Cancer. Annals of Surgical Oncology, 21, 738-746. [Google Scholar] [CrossRef] [PubMed]
[22] Tsikitis, V.L., et al. (2009) Postoperative Surveillance Recom-mendations for Early Stage Colon Cancer Based on Results from the Clinical Outcomes of Surgical Therapy Trial. Jour-nal of Clinical Oncology, 27, 3671-3676. [Google Scholar] [CrossRef] 
[23] Goldstein, M.J. and Mitchell, E.P. (2005) Carcinoembryonic Anti-gen in the Staging and Follow-up of Patients with Colorectal Cancer. Cancer Investigation, 23, 338-351. [Google Scholar] [CrossRef] 
[24] Compton, C., Fenoglio-Preiser, C.M., Pettigrew, N. and Fielding, L.P. (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer, 88, 1739-1757. [Google Scholar] [CrossRef] 
[25] 鞠鹏飞. 血清肿瘤标记物对结直肠癌腹膜转移预判的研究[D]: [硕士学位论文]. 青岛: 青岛大学, 2020.
[26] Saito, G., et al. (2017) Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence. Oncology, 92, 276-282. [Google Scholar] [CrossRef] [PubMed]
[27] 武天同. CEA、CA19-9和CA72-4联检在结直肠癌预后中的临床研究[D]: [硕士学位论文]. 广州: 南方医科大学, 2018.
[28] 石方玉. Ki67、EGFR、P53及血清肿瘤标记物CEA、CA199对结直肠癌预后的价值分析[D]: [硕士学位论文]. 承德: 承德医学院, 2022.
[29] 王文军, 杨伏猛, 刘倩. D二聚体和肿瘤标志物与结直肠癌的相关性研究[J]. 中国继续医学教育, 2018, 10(2): 55-56.
[30] 蔡丽彬. 血浆循环游离DNA与CEA在结直肠癌中的临床研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2018.
[31] 邓子昂, 李洋, 杨作磊, 冉锐. 血浆Septin9甲基化和血清CEA联合检测在结直肠癌诊断中的临床意义[J]. 现代医药卫生, 2020, 36(11): 1628-1630+1633.
[32] 龙华婧, 邱芳华, 刘道利, 刘燕娣, 周意, 吴嘉怡. 血清肿瘤标记物与多层螺旋CT、肠镜及病理联合检查对结直肠癌的诊断价值[J]. 国际检验医学杂志, 2019, 40(15): 1802-1806+1810.
[33] Kantor, J., et al. (1992) Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate. Cancer Research, 52, 6917-6925.
[34] Hance, K.W., Zeytin, H.E. and Greiner, J.W. (2005) Mouse Models Expressing Human Carcinoembryonic Antigen (CEA) as a Transgene: Evaluation of CEA-Based Cancer Vaccines. Mutation Research, 576, 132-154. [Google Scholar] [CrossRef] [PubMed]
[35] Bei, R. and Scardino, A. (2010) TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy. BioMed Research International, 2010, Article ID: 102758. [Google Scholar] [CrossRef] [PubMed]
[36] Marshall, J.L., et al. (2000) Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonrepli-cating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses. Journal of Clinical Oncology, 18, 3964-3973. [Google Scholar] [CrossRef] 
[37] Conry, R.M., et al. (2000) Human Autoantibodies to Carci-noembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine. Clinical Cancer Research, 6, 34-41.
[38] von Mehren, M., et al. (2001) The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma. Clinical Can-cer Research, 7, 1181-1191.
[39] Zeytin, H.E., et al. (2004) Combination of a Poxvirus-Based Vaccine with a Cy-clooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice. Can-cer Research, 64, 3668-3678. [Google Scholar] [CrossRef] 
[40] Oun, R., Moussa, Y.E. and Wheate, N.J. (2018) The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists. Dalton Transactions, 47, 6645-6653. [Google Scholar] [CrossRef] 
[41] Dinarvand, R., Sepehri, N., Manoochehri, S., Rouhani, H. and Atyabi, F. (2011) Polylactide-Co-Glycolide Nanoparticles for Controlled Delivery of Anticancer agents. International Journal of Nanomedicine, 6, 877-895. [Google Scholar] [CrossRef] 
[42] Perkins, G.L., Slater, E.D., Sanders, G.K. and Prichard, J.G. (2003) Se-rum Tumor Markers. American Family Physician, 68, 1075-1082.
[43] Murthy, S.K. (2007) Nanoparticles in Modern Medicine: State of the Art and Future Challenges. International Journal of Nanomedicine, 2, 129-141.
[44] Pereira, I., Sousa, F., Kennedy, P. and Sarmento, B. (2018) Carcinoembryonic Antigen-Targeted Nanoparticles Potentiate the Deliv-ery of Anticancer Drugs to Colorectal Cancer Cells. International Journal of Pharmaceutics, 549, 397-403. [Google Scholar] [CrossRef] [PubMed]
[45] Ji, X., Lv, H., Sun, X. and Ding, C. (2019) Green-Emitting Carbon Dot Loaded Silica Nanoparticles Coated with DNA-Cross-Linked Hydrogels for Sensitive Carcinoembryonic Antigen Detection and Effective Targeted Cancer Therapy. Chemical Communications, 55, 15101-15104. [Google Scholar] [CrossRef] 
[46] Boogerd, L.S.F., et al. (2018) Safety and Effectiveness of SGM-101, a Fluorescent Antibody Targeting Carcinoembryonic Antigen, for Intraoperative Detection of Colorectal Cancer: A Dose-Escalation Pilot Study. The Lancet Gastroenterology and Hepatology, 3, 181-191. [Google Scholar] [CrossRef] 
[47] de Valk, K.S., et al. (2021) Dose-Finding Study of a CEA-Targeting Agent, SGM-101, for Intraoperative Fluorescence Imaging of Colorectal Cancer. Annals of Surgical Oncology, 28, 1832-1844. [Google Scholar] [CrossRef] [PubMed]

为你推荐